Skip to main content

DurAct Disease Interactions

There are 4 disease interactions with DurAct (bromfenac).

Major

NSAIDs (applies to DurAct) GI toxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Intestinal Anastomoses

Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can develop at any time, with or without warning symptoms. NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as: prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy. Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
  2. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  3. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  4. (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
  5. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  6. (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
  7. (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
  8. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  9. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  10. (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
  11. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  12. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  13. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  14. (2001) "Product Information. Daypro (oxaprozin)." Searle
  15. (2001) "Product Information. Celebrex (celecoxib)." Searle
  16. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
View all 16 references
Moderate

NSAIDs (applies to DurAct) heart failure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure

Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations. These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.

References

  1. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  2. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  3. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  5. (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
  6. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  7. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  8. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Daypro (oxaprozin)." Searle
  10. (2001) "Product Information. Celebrex (celecoxib)." Searle
  11. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  12. (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
View all 12 references
Moderate

NSAIDs (applies to DurAct) hyperkalemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Caution is advised in patients with hyperkalemia.

References

  1. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  2. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  3. (2001) "Product Information. Celebrex (celecoxib)." Searle
Moderate

NSAIDs (applies to DurAct) hypertension

Moderate Potential Hazard, Moderate plausibility.

Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.

References

  1. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  2. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  3. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  5. (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
  6. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  7. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  8. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Daypro (oxaprozin)." Searle
  10. (2001) "Product Information. Celebrex (celecoxib)." Searle
  11. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  12. (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
View all 12 references

DurAct drug interactions

There are 342 drug interactions with DurAct (bromfenac).

DurAct alcohol/food interactions

There are 2 alcohol/food interactions with DurAct (bromfenac).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.